Galmed pharmaceuticals launches vcu collaboration to tackle drug resistance in gi cancers

Galmed pharmaceuticals (nasdaq: glmd) enters into a sponsored project agreement with virginia commonwealth university (vcu) to evaluate aramchol's effect on overcoming drug resistance in gastrointestinal (gi) cancers. aramchol, a first-in-class scd1 inhibitor, will be studied in combination with standard therapies for advanced colorectal and liver cancers, aiming to reverse treatment resistance and improve outcomes in these high-mortality cancers.
GLMD Ratings Summary
GLMD Quant Ranking